机构:[1]Senior Department of Infectious Diseases, the Fifth Medical Center of ChinesePLA General Hospital, National Clinical Research Center for Infectious Diseases, Savaid Medical School, University of Chinese Academy of Sciences,Beijing 100039, China[2]Department of Infectious Diseases and Hepatology,the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052,China[3]Biomedical Pioneering Innovation Center (BIOPIC), School of Life Sciences, Peking University, Beijing 100871, China[4]Yunnan Infectious Disease Hospital, Kunming 650301, China[5]Third People’s Hospital of Shenzhen,School of Medicine, Southern University of Science and Technology, Shenzhen518112, Guangzhou, China
Background Mucosal-associated invariant T (MAIT) cells are systemically depleted in human immunodeficiency virus type 1 (HIV-1) infected patients and are not replenished even after successful combined antiretroviral therapy (cART). This study aimed to identify the mechanism underlying MAIT cell depletion. Methods In the present study, we applied flow cytometry, single-cell RNA sequencing and immunohistochemical staining to evaluate the characteristics of pyroptotic MAIT cells in a total of 127 HIV-1 infected individuals, including 69 treatment-naive patients, 28 complete responders, 15 immunological non-responders, and 15 elite controllers, at the Fifth Medical Center of Chinese PLA General Hospital, Beijing, China. Results Single-cell transcriptomic profiles revealed that circulating MAIT cells from HIV-1 infected subjects were highly activated, with upregulation of pyroptosis-related genes. Further analysis revealed that increased frequencies of pyroptotic MAIT cells correlated with markers of systemic T-cell activation, microbial translocation, and intestinal damage in cART-naive patients and poor CD4(+) T-cell recovery in long-term cART patients. Immunohistochemical staining revealed that MAIT cells in the gut mucosa of HIV-1 infected patients exhibited a strong active gasdermin-D (GSDMD, marker of pyroptosis) signal near the cavity side, suggesting that these MAIT cells underwent active pyroptosis in the colorectal mucosa. Increased levels of the proinflammatory cytokines interleukin-12 (IL-12) and IL-18 were observed in HIV-1 infected patients. In addition, activated MAIT cells exhibited an increased pyroptotic phenotype after being triggered by HIV-1 virions, T-cell receptor signals, IL-12 plus IL-18, and combinations of these factors, in vitro. Conclusions Activation-induced MAIT cell pyroptosis contributes to the loss of MAIT cells in HIV-1 infected patients, which could potentiate disease progression and poor immune reconstitution.
基金:
Peking University Clinical Scientist Program Special [BMU2019LCKXJ013]; National Natural Science Foundation Innovation Research Group Project [81721002]; Sanming Project of Medicine Project in Shenzhen [SZSM201612014]; Yunnan Applied Basic Research Projects-Union Foundation by Yunnan Provincial Department of Science and Technology; Kunming Medical University [202001AY070001-154]; Scientific Research Fund of Education Department of Yunnan Province [2021J0297]
第一作者机构:[1]Senior Department of Infectious Diseases, the Fifth Medical Center of ChinesePLA General Hospital, National Clinical Research Center for Infectious Diseases, Savaid Medical School, University of Chinese Academy of Sciences,Beijing 100039, China[2]Department of Infectious Diseases and Hepatology,the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052,China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Xia Peng,Xing Xu-Dong,Yang Cui-Xian,et al.Activation-induced pyroptosis contributes to the loss of MAIT cells in chronic HIV-1 infected patients[J].MILITARY MEDICAL RESEARCH.2022,9(1):doi:10.1186/s40779-022-00384-1.
APA:
Xia, Peng,Xing, Xu-Dong,Yang, Cui-Xian,Liao, Xue-Jiao,Liu, Fu-Hua...&Zhang, Ji-Yuan.(2022).Activation-induced pyroptosis contributes to the loss of MAIT cells in chronic HIV-1 infected patients.MILITARY MEDICAL RESEARCH,9,(1)
MLA:
Xia, Peng,et al."Activation-induced pyroptosis contributes to the loss of MAIT cells in chronic HIV-1 infected patients".MILITARY MEDICAL RESEARCH 9..1(2022)